Any hope for renal denervation after SYMPLICITY HTN-3?

Peter A. Brady, M.B., Ch.B., M.D., Mayo Clinic electrophysiologist and director of the Heart Rhythm and Physiological Monitoring Lab, and Rajiv Gulati, M.D., Ph.D., cardiologist and associate professor of medicine, discuss renal denervation following the SYMPLICITY HTN-3 trial. Were prior trials positive because of bias and open label and the first well-done control trial showed that the technology doesn't work? Or was the technology not sufficient to induce denervation?


June 1, 2015

Created by

Mayo Clinic